137 related articles for article (PubMed ID: 2469104)
21. [Results of the treatment of patients with advanced Hodgkin's disease by the ABDiC and/or BVCPP protocols].
Leszko B; Słomkowski M; Pawelski S; Kopeć I; Maj S
Acta Haematol Pol; 1989; 20(1):36-41. PubMed ID: 2482648
[TBL] [Abstract][Full Text] [Related]
22. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
[TBL] [Abstract][Full Text] [Related]
23. [A trial of applying an oily suspension of bleomycin endolymphatically in patients with Hodgkin's disease of the extraperitoneal lymph nodes].
Ziółko E
Pol Merkur Lekarski; 1997 Jul; 3(13):8-9. PubMed ID: 9432303
[TBL] [Abstract][Full Text] [Related]
24. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV].
Lopez M
Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542
[No Abstract] [Full Text] [Related]
25. MOPP, ABVD, or both to treat Hodgkin's disease.
Martino R; Nomdedeu J; Brunet S
N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680766
[No Abstract] [Full Text] [Related]
26. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
Bonadonna G; Santoro A; Bonfante V; Valagussa P
Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323
[TBL] [Abstract][Full Text] [Related]
27. [Treatment outcome of advanced Hodgkin's disease based on using an alternating program ChLVPP (chlorambucil, vinblastine, procarbazine, prednisone) and ABV (doxorubicin, bleomycin, vinblastine)].
Komarnicki M; Balcerzak A; Górski P; Pawlak L; Hansz J
Acta Haematol Pol; 1994; 25(4):363-8. PubMed ID: 7531381
[TBL] [Abstract][Full Text] [Related]
28. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
[TBL] [Abstract][Full Text] [Related]
29. Clinical investigations of children with Hodgkin's disease at Stanford University Medical Center. A preliminary overview using low-dose irradiation and alternating ABVD/MOPP chemotherapy.
Donaldson SS; Link MP; McDougall IR; Parker BR; Shochat SJ
Cancer Treat Res; 1989; 41():307-15. PubMed ID: 2484294
[No Abstract] [Full Text] [Related]
30. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
[TBL] [Abstract][Full Text] [Related]
31. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
32. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
[TBL] [Abstract][Full Text] [Related]
33. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
[TBL] [Abstract][Full Text] [Related]
34. [Combination chemotherapy of Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
Aiba K; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Dohmyo M; Nagata T; Miyamoto H; Kobayashi T; Kuraishi Y
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1928-32. PubMed ID: 6897857
[TBL] [Abstract][Full Text] [Related]
35. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease.
Brusamolino E; Lazzarino M; Morra E; Inverardi D; Merante S; Castelli G; Canevari A; Dornini G; Bernasconi C
Haematologica; 1989; 74(2):173-9. PubMed ID: 2473013
[TBL] [Abstract][Full Text] [Related]
36. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
37. [Early results of the treatment of Hodgkin's disease in adults using the seven-drug cytostatic protocol].
Kotlarek-Haus S; Gabryś K; Wołowiec D; Kuliszkiewicz-Janus M; Filip A
Pol Arch Med Wewn; 1992 Feb; 87(2):134-43. PubMed ID: 1381821
[TBL] [Abstract][Full Text] [Related]
38. [Relapse of Hodgkin disease after 17 years of complete remission. A case report].
Osorio G; Caglevic C
Rev Med Chil; 2003 Feb; 131(2):197-9. PubMed ID: 12708259
[TBL] [Abstract][Full Text] [Related]
39. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
Bonadonna G; Viviani S; Bonfante V; Gianni AM; Valagussa P
Eur J Cancer; 2005 May; 41(7):998-1006. PubMed ID: 15862748
[TBL] [Abstract][Full Text] [Related]
40. [A case of Hodgkin's disease of mesenteric origin].
Morita M; Tani S; Hagihara R; Ryu Y; Yagi N; Yamashita J; Imanishi K; Kitazawa S
Nihon Shokakibyo Gakkai Zasshi; 2002 Apr; 99(4):391-6. PubMed ID: 11979737
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
